RIL
ESPR

Rothschild Investment LLC’s Esperion Therapeutics ESPR Stock Holding History

Rothschild Investment LLC’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-100
Closed -$220 – 3043
2024
Q4 		$220 Buy
100
+40
+67% +$93 ﹤0.01% 2773
2024
Q3 		$99 Hold
60
– – ﹤0.01% 2850
2024
Q2 		$133 Buy
+60
New +$141 ﹤0.01% 2619

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $780M AUM 24.84% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Rothschild Investment LLC's ESPR Position: Q1 2025 in Review

Rothschild Investment LLC sold out of Esperion Therapeutics (ESPR) in Q1 2025, closing a stake of 100 shares — an estimated $220 sold.

Rothschild Investment LLC first reported a position in ESPR in Q2 2024 and held it in 3 quarters. The position peaked at $220 in Q4 2024. 186 funds tracked by Wall St. Rank hold ESPR as of Q1 2025.

  • Rothschild Investment LLC reported no remaining Esperion Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Rothschild Investment LLC sold 100 Esperion Therapeutics shares in Q1 2025, an estimated $220.
  • Rothschild Investment LLC first reported a position in Esperion Therapeutics in Q2 2024 and held it in 3 quarters.
  • Rothschild Investment LLC's Esperion Therapeutics position peaked at $220 in Q4 2024.
  • 186 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2025.

Based on Rothschild Investment LLC's 13F filing for Q1 2025, filed 8 Apr 2025.